Cargando…

Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?

Immune checkpoint inhibitors (ICIs) are beginning to show promise in the clinical management of hepatocellular carcinoma (HCC). Most recently, the anti-programmed death protein-1 (PD-1) agent atezolizumab combined with bevacizumab demonstrated superiority to sorafenib in a Phase 3 randomised clinica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tovoli, Francesco, De Lorenzo, Stefania, Trevisani, Franco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7711845/ https://www.ncbi.nlm.nih.gov/pubmed/33023131 http://dx.doi.org/10.3390/vaccines8040578

Ejemplares similares

Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma
por: De Lorenzo, Stefania, et al.
Publicado: (2022)

Immunotherapy and Hepatocellular Cancer: Where Are We Now?
por: Valery, Marine, et al.
Publicado: (2022)

Liquid Biopsy in Hepatocellular Carcinoma: Where Are We Now?
por: Pelizzaro, Filippo, et al.
Publicado: (2021)

Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?
por: Jang, Albert, et al.
Publicado: (2021)

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Oral Immunotherapy in Food Allergy: Where Are We Now?
por: Özdemir, Pınar Gökmirza, et al.
Publicado: (2023)

Peptide-based immunotherapy in lupus: Where are we now?
por: P. Singh, Ram, et al.
Publicado: (2023)

Hepatocellular adenoma: Where are we now?
por: Wang, Xi, et al.
Publicado: (2022)

Aromatase inhibitors--where are we now?
por: Miller, W. R.
Publicado: (1996)

Immunotherapy after liver transplantation: Where are we now?
por: Au, Kin Pan, et al.
Publicado: (2021)

Onchodermatitis: Where Are We Now?
por: Murdoch, Michele E.
Publicado: (2018)

The Role of Circulating Biomarkers in the Oncological Management of Metastatic Renal Cell Carcinoma: Where Do We Stand Now?
por: Cinque, Alessandra, et al.
Publicado: (2021)

Immune checkpoint inhibitors in the treatment of oesophageal squamous cell carcinoma: where are we and where are we going?
por: Chen, Ning, et al.
Publicado: (2023)

Melanoma Immunotherapy and Precision Medicine in the Era of Tumor Micro-Tissue Engineering: Where Are We Now and Where Are We Going?
por: Varrone, Francesca, et al.
Publicado: (2021)

Lysine methyltransferase inhibitors: where we are now
por: Feoli, Alessandra, et al.
Publicado: (2021)

Angiogenesis inhibitors in clinical development; where are we now and where are we going?
por: Eskens, F A L M
Publicado: (2004)

Where are we now and where are we headed?
por: Langan, Ewan A.
Publicado: (2023)

Aging with Down Syndrome—Where Are We Now and Where Are We Going?
por: Alldred, Melissa J., et al.
Publicado: (2021)

Where are we now?
Publicado: (1977)

Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go
por: Wang, Kunpeng, et al.
Publicado: (2021)

Microbiota and Obesity: Where Are We Now?
por: Ballini, Andrea, et al.
Publicado: (2020)

Liquid Biopsy in the Management of Breast Cancer Patients: Where Are We Now and Where Are We Going
por: Mazzitelli, Carlotta, et al.
Publicado: (2023)

Depression research: where are we now?
por: Lee, Saebom, et al.
Publicado: (2010)

Calcaneal fractures: Where are we now?
por: Razik, Aisha, et al.
Publicado: (2017)

Osteopontin and Transplantation: Where Are We Now?
por: Kaleta, Beata
Publicado: (2021)

Genetics of migraine: where are we now?
por: Grangeon, Lou, et al.
Publicado: (2023)

Vesicoureteral Reflux: Where Have We Been, Where Are We Now, and Where Are We Going?
por: McLorie, Gordon A.
Publicado: (2008)

Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going
por: Omarini, Claudia, et al.
Publicado: (2018)

Targeting therapy in pemphigus: Where are we now and where are we going?
por: Abulikemu, Kailibinuer, et al.
Publicado: (2023)

CAR-T cell therapy: Where are we now, and where are we heading?
por: Wang, Jia-Yi, et al.
Publicado: (2023)

Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Where Are We Now and Where Are We Headed?
por: Dixon-Douglas, Julia, et al.
Publicado: (2023)

Pim kinases in hematological malignancies: where are we now and where are we going?
por: Mondello, Patrizia, et al.
Publicado: (2014)

A Comprehensive Review on Bariatric Endoscopy: Where We Are Now and Where We Are Going
por: Mauro, Aurelio, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance
por: Pelizzaro, Filippo, et al.
Publicado: (2023)

Cardiovascular Tissue Engineering: Where We Come From and Where Are We Now?
por: Smit, Francis E., et al.
Publicado: (2015)

Reflection for the undergraduate on writing in the portfolio: where are we now and where are we going?
por: AHMED, MOHAMED H
Publicado: (2018)

Future Perspectives in Pediatric Dentistry: Where are We Now and where are We Heading?
por: Rodrigues, Jonas A, et al.
Publicado: (2022)

Pediatric SJS-TEN: Where are we now?
por: Ramien, Michele, et al.
Publicado: (2020)

Pioglitazone in Clinical Practice: Where Are We Now?
por: Govindan, Joytish, et al.
Publicado: (2012)

Treatment of uveal melanoma: where are we now?
por: Yang, Jessica, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_n8q8m5mv3eed0fio13j7atd935